US 11,753,633 B2
Compositions and methods for treatment of pain
R. John Collier, Wellesley, MA (US); Isaac Chiu, Brookline, MA (US); Bradley L. Pentelute, Cambridge, MA (US); Keith Alan Foster, Salisbury (GB); Shilpa Palan, Yarnton (GB); and Sai Man Liu, Oxford (GB)
Assigned to President and Fellows of Harvard College, Cambridge, MA (US); Massachusetts Institute of Technology, Cambridge, MA (US); and IPSEN PHARMA S.A.S., Boulogne-Billancourt (FR)
Appl. No. 15/755,544
Filed by President and Fellows of Harvard College, Cambridge, MA (US); Massachusetts Institute of Technology, Cambridge, MA (US); and IPSEN PHARMA S.A.S., Boulogne-Billancourt (FR)
PCT Filed Aug. 26, 2016, PCT No. PCT/US2016/049106
§ 371(c)(1), (2) Date Feb. 26, 2018,
PCT Pub. No. WO2017/035508, PCT Pub. Date Mar. 2, 2017.
Claims priority of provisional application 62/210,610, filed on Aug. 27, 2015.
Prior Publication US 2018/0244731 A1, Aug. 30, 2018
Int. Cl. A61K 39/07 (2006.01); A61K 39/08 (2006.01); C07K 14/32 (2006.01); C07K 14/33 (2006.01); C12N 9/52 (2006.01); C12N 9/50 (2006.01); A61P 29/00 (2006.01)
CPC C12N 9/52 (2013.01) [A61K 39/07 (2013.01); A61K 39/08 (2013.01); A61P 29/00 (2018.01); C07K 14/32 (2013.01); C07K 14/33 (2013.01); C12N 9/50 (2013.01); C07K 2319/01 (2013.01); C07K 2319/55 (2013.01)] 30 Claims
 
1. A method for treatment of pain, the method comprising administering to a subject in need thereof a composition comprising a nucleic acid that encodes a fusion protein, wherein the fusion protein comprises:
a botulinum neurotoxin (BTx) moiety, wherein the BTx moiety comprises (i) a BTx enzymatic moiety capable of cleaving a SNARE protein and (ii) a BTx translocation domain, and
a targeting moiety comprising a C-terminal receptor-binding domain of an anthrax toxin protective antigen (PA), wherein the C-terminal receptor-binding domain of PA comprises a PAd4 domain,
wherein the BTx moiety and the targeting moiety are linked or fused together.